Elopag 25 MG (Eltrombopag)

Basic Product Information of Elopag 25 MG (Eltrombopag)

How Elopag 25 MG (Eltrombopag) Works: Thrombopoietin Receptor Agonism

Eltrombopag, the active ingredient in Elopag 25 MG, is a selective, orally bioavailable small-molecule agonist of the thrombopoietin receptor (TPO-R), also known as c-Mpl. The thrombopoietin receptor is expressed on the surface of megakaryocyte progenitor cells in the bone marrow. When eltrombopag binds to the transmembrane domain of c-Mpl at a site distinct from where endogenous thrombopoietin (TPO) binds it initiates intracellular signalling through the JAK2 and STAT pathways, which drives megakaryocyte proliferation, differentiation, and maturation, ultimately increasing platelet production and release into the bloodstream.

Because eltrombopag targets a binding site distinct from endogenous TPO, it can act additively with circulating TPO rather than competing with it. This mechanism makes Elopag 25 MG clinically relevant in conditions where platelet counts are dangerously low due to accelerated peripheral destruction (as in chronic ITP), suppressed bone marrow production (as in severe aplastic anemia), or TPO-resistant thrombocytopenia (as in chronic hepatitis C). Patients and oncologists coordinating complex blood disorder management can review the broader range of oncology and haematology medicines available at Mediaid Pharmacy for supportive and companion therapies.

In the pivotal RAISE trial (chronic ITP), eltrombopag produced a platelet response (platelets ≥50 × 10⁹/L) in 59% of patients versus 16% on placebo over the 6-month treatment period (odds ratio 9.61; p <0.0001). Eltrombopag also significantly reduced the rate of clinically significant bleeding events and decreased the need for rescue medication. Notably, a starting dose of 25 mg once daily is the reference label recommendation for East Asian patients including Bangladeshi patients and for those with mild-to-moderate hepatic impairment, making the Elopag 25 MG strength directly relevant to this population.

Approved Indications of Eltrombopag (Reference Label for Elopag 25 MG (Eltrombopag))

Eltrombopag, the active ingredient in Elopag 25 MG, is approved internationally across three distinct clinical settings involving thrombocytopenia. Prescribers in Bangladesh should confirm the exact locally approved indications on the Elopag product label.

Key Clinical Benefits of Elopag 25 MG (Eltrombopag)

Dosage and Administration of Elopag 25 MG (Eltrombopag)

Clinical Monitoring Requirements During Elopag 25 MG (Eltrombopag) Treatment

Regular monitoring is mandatory throughout eltrombopag therapy. Hepatotoxicity is the most clinically significant non-haematologic risk. The reference label requires liver function tests (ALT, AST, and bilirubin) at baseline, every 2 weeks during the dose-adjustment phase, and monthly once a stable dose is established. Eltrombopag must be discontinued if ALT rises to ≥3× the upper limit of normal with signs of hepatic dysfunction, is ≥3× baseline in patients with elevated pre-treatment values, or is ≥5× the upper limit of normal and persistent.

Platelet count monitoring is required weekly during dose initiation and adjustment, then monthly once stable. Maintaining the platelet count in the target range (50–200 × 10⁹/L for ITP) is essential, because supratherapeutic platelet counts increase the risk of thromboembolic events including deep vein thrombosis and portal vein thrombosis. Peripheral blood smears and complete blood counts should be reviewed monthly for morphological changes consistent with bone marrow fibrosis, an uncommon but serious complication. Ophthalmic examination for cataracts should be performed at baseline and periodically during treatment, since lens changes have been reported with eltrombopag.

Drug Interactions and Important Safety Information for Elopag 25 MG (Eltrombopag)

The most clinically important interaction for eltrombopag is chelation by polyvalent cations. Foods and medications containing calcium (dairy products, calcium-fortified juices, antacids), aluminum, magnesium, iron, selenium, or zinc bind eltrombopag in the gastrointestinal tract and can reduce drug absorption by up to 70%. Patients must take Elopag 25 MG tablets on an empty stomach, at least 2 hours before or 4 hours after any polyvalent cation-containing product. This is the single most important administration instruction for maintaining adequate drug exposure.

Eltrombopag is an inhibitor of the drug transporters OATP1B1 and OATP1B3. Co-administration with rosuvastatin increases rosuvastatin plasma exposure by approximately 55%; the rosuvastatin dose should be reduced and patients monitored for statin-related adverse effects. Eltrombopag is also a substrate of CYP1A2 and CYP2C8, so strong inhibitors of these enzymes (ciprofloxacin, fluvoxamine, gemfibrozil) may increase eltrombopag exposure. Patients must provide their prescribing physician with a complete list of all current medications prescription, over-the-counter, and herbal before starting eltrombopag. Anticoagulants and antiplatelet agents should be used cautiously because excessive platelet elevation increases clot risk, while excess platelet suppression increases bleeding risk if the dose is not titrated correctly.

Side Effects and Precautions of Elopag 25 MG (Eltrombopag)

Who Should Use Elopag 25 MG (Eltrombopag)?

Elopag 25 MG (Eltrombopag) is prescribed for adults and paediatric patients (aged 1 year and older) with chronic immune thrombocytopenic purpura (ITP) who have not responded adequately to corticosteroids, immunoglobulins, or splenectomy. It is also prescribed for adults with severe aplastic anemia (SAA) who did not respond to immunosuppressive therapy, or as part of first-line combination immunosuppression for treatment-naïve SAA. The 25 mg starting dose is the reference label recommendation for East Asian patients including Bangladeshi patients and for those with mild-to-moderate hepatic impairment, making Elopag 25 MG particularly well-suited to clinical practice in Bangladesh. Prescribers assess baseline liver function, platelet count, blood smear morphology, and eye health before initiating treatment. Elopag 25 MG is prescribed by haematologists and specialist physicians experienced with thrombopoietin receptor agonist therapy. For patients who need broader haematology and cancer care support, Mediaid Pharmacy’s oncology specialty medicines range offers a wide selection of targeted and supportive therapies.

Global Supplier: Mediaid Pharmacy Worldwide Shipping for Elopag 25 MG (Eltrombopag)

Mediaid Pharmacy is a Dhaka-based supplier of oncology and specialty medicines with worldwide shipping. Elopag 25 MG (Eltrombopag) is available in 14’s and 28’s tablet packs, and orders are supported by pricing quotations, stock confirmation, documentation, and delivery tracking. Hospitals, distributors, and patients can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all questions about Elopag 25 MG Eltrombopag availability, pricing, and international delivery. Buyers who need several haematology or oncology medicines in one consignment can browse the full oncology medicine collection before requesting a combined quotation.

Why Choose Elopag 25 MG (Eltrombopag) from Mediaid Pharmacy?

Elopag 25 MG (Eltrombopag) gives haematology and specialist teams a Bangladesh-registered eltrombopag tablet for ITP, severe aplastic anemia, and hepatitis C-associated thrombocytopenia, backed by the clinical evidence generated in the RAISE, EXTEND, and SAA Phase II/III trials. The 25 mg strength is the guideline-recommended starting dose for East Asian including Bangladeshi patients and those with hepatic impairment, reflecting precise clinical alignment with the local patient population. Mediaid Pharmacy supplies Elopag 25 MG in 14’s and 28’s packs with clear product specifications, direct specialist support, and worldwide shipping. Every order starts with a prescription-based enquiry, which keeps supply aligned with clinical need. To compare eltrombopag with other targeted haematology agents or to source additional cancer and blood disorder therapies, visit the Mediaid Pharmacy oncology medicines section, then contact our team for a personalised quotation.

Frequently Asked Questions About Elopag 25 MG (Eltrombopag)